This application is related to the following commonly-assigned application entitled “Methods, Systems and Apparatuses for Detecting Increased Risk of Sudden Death,” U.S. application Ser. No. 13/453,746, filed May 10, 2012, herein incorporated in its entirety by reference.
The present disclosure relates generally to the field of medical systems for detecting seizures. More particularly, the disclosure relates to systems, methods and apparatuses for using an accelerometer based system for detecting seizure and non-seizure states in patients experiencing seizures.
The embodiments described herein relate generally to the field of medical systems for detecting seizures. “A seizure is an abnormal, unregulated electrical charge that occurs within the brain's cortical gray matter and transiently interrupts normal brain function.” The Merck Manual of Diagnosis and Therapy, 1822 (M. Beers Editor in Chief, 18th ed. 2006) (“Merck Manual”). Epilepsy is a chronic disease characterized by such seizures, but not caused by an event such as a stroke, drug use, or physical injury. Seizures may vary in frequency and scope and may range from involving no impairment of consciousness at all to complete loss of consciousness. Typically, a seizure resolves within a few minutes and extraordinary medical intervention, other than that needed for the comfort of the patient and to promote unobstructed breathing, is not needed. (See, generally, Merck Manual at 1822-1827, incorporated herein by reference.)
If a patient is aware that a seizure is beginning, the patient may prepare for the seizure by ceasing activity that may be dangerous should a seizure begin, assuming a comfortable position, and/or alerting friends or family. In some patients, an implanted neurostimulator, such as that described in U.S. Pat. No. 5,304,206, incorporated herein by reference, may be activated, which may allow the patient to avoid the seizure, limit the seizure severity and/or duration, or shorten the patient's recovery time. Some patients may not experience onset symptoms indicating that a seizure is imminent or beginning In addition, others may not be aware a seizure has taken place. A record of the frequency, duration, and severity of seizures is an important tool in diagnosing the type of seizures that are occurring and in treating the patient.
Accelerometers have been known for detecting movement in seizure patients. See, for example, U.S. Pat. No. 5,304,206, column 8, lines 28-33. (“A motion sensor is provided within the bracelet for automatically detecting movements by the patient. The motion sensor portion of the detection system 78 (FIG. 6) may be of any known type, such as an accelerometer or a vibration sensor, but preferably, is a contact-type sensor as shown in principal part in FIG. 9.”) An accelerometer measures “proper acceleration” of an object. Proper acceleration is different than the more familiar concept of “coordinate acceleration.” Coordinate acceleration is a change in velocity of an object with respect to its surroundings, such as an automobile accelerating from zero to 60 miles per hour in a given number of seconds.
By contrast, proper acceleration is the physical acceleration of an object relative to an observer who is in free fall. Proper acceleration is measured in units of “g-force” or gravity/seconds2. Proper acceleration can also be considered to be weight of an object per unit of mass. When an object sits motionless on the ground, its coordinate acceleration is zero. But to determine the object's proper acceleration, one compares the object to the observer in free fall, who is falling towards the center of the Earth. A force acts on the motionless object that is not acting on the observer in free fall: the force of the Earth is pushing up on the object, holding it in place, so the motionless object has a proper acceleration of 1 gravity/second2.
An accelerometer may be used to determine a sudden change of position of a person, which might be indicative of a seizure in the person with physical symptoms. Both the amplitude of the change in position and the frequency of the change in position could be important indications of a seizure, depending in part on how seizures affect a particular patient. Of course, a change of position may have a non-seizure cause, as people sometimes engage in strenuous activities. Most algorithms used to analyze accelerometer data are highly complex, making them inconvenient to use. The use of some accelerometer algorithms requires training and position correction. Most of the current algorithms used to analyze accelerometer data also require that the accelerometer be held in a proper orientation.
Accordingly, a need is present for methods, systems and apparatuses to better detect seizures and/or overcome issues discussed above.
The embodiments of the disclosure described herein include a system including at least one accelerometer positioned on a patient and configured to collect acceleration data and a processor in communication with the at least one accelerometer and configured to receive acceleration data from the at least one accelerometer. The processor may apply one or more non-linear operators to the acceleration data to determine whether the acceleration data indicates an event. Application of the non-linear operator to the acceleration data may include calculation of a non-linear energy of the acceleration data and performance of at least one secondary analysis to determine whether the event is a seizure.
The embodiments of the present disclosure also include an apparatus, which includes at least one accelerometer for positioning on a patient, the at least one accelerometer configured to collect acceleration data and a processor in communication with the at least one accelerometer, configured to receive acceleration data from the at least one accelerometer. The processor is configured to apply a non-linear operator to the acceleration data to determine whether the acceleration data indicates an event, wherein application of the non-linear operator to the acceleration data includes calculation of a non-linear energy of the acceleration data and performance of at least one secondary analysis to determine whether the event is a seizure.
The embodiments of the present disclosure also include a method. The steps of the method include receiving acceleration data at a processor from at least one accelerometer positioned on the patient and applying a non-linear operator to the acceleration data at the processor to determine whether the acceleration data indicates an event, wherein applying the non-linear operator to the acceleration data includes calculating a non-linear energy of the acceleration data.
Other aspects and advantages of the embodiments described herein will become apparent from the following description and the accompanying drawings, illustrating the principles of the embodiments by way of example only.
Features and advantages of the present disclosure will become apparent from the appended claims, the following detailed description of one or more example embodiments, and the corresponding figures.
While the disclosure is subject to various modifications and alternative forms, specific embodiments thereof are shown by way of example in the drawings and the accompanying detailed description. It should be understood, however, that the drawings and detailed description are not intended to limit the disclosure to the particular embodiments. This disclosure is instead intended to cover all modifications, equivalents, and alternatives falling within the scope of the present disclosure as defined by the appended claims.
The drawing figures are not necessarily to scale and certain features may be shown exaggerated in scale or in somewhat generalized or schematic form in the interest of clarity and conciseness. In the description which follows, like parts may be marked throughout the specification and drawing with the same reference numerals. The foregoing description of the figures is provided for a more complete understanding of the drawings. It should be understood, however, that the embodiments are not limited to the precise arrangements and configurations shown. Although the design and use of various embodiments are discussed in detail below, it should be appreciated that the present disclosure provides many inventive concepts that may be embodied in a wide variety of contexts. The specific aspects and embodiments discussed herein are merely illustrative of ways to make and use the disclosure, and do not limit the scope of the disclosure. It would be impossible or impractical to include all of the possible embodiments and contexts of the disclosure in this disclosure. Upon reading this disclosure, many alternative embodiments of the present disclosure will be apparent to persons of ordinary skill in the art.
If the event is a seizure event, the processor 115 can also send an activation signal 130 to the warning device 135. The warning device 135 could, for example, activate an alarm with a sound or a vibration. The warning device 135 could also place a call with a recorded message, or send an e-mail or a text message, to one or more designated persons. In addition, a therapy, such as electrical stimulation to a cranial nerve or brain tissue, may be provided in place of, simultaneously with, or following the warning provided by the warning device 135.
Continuing to refer to
Continuing to refer to
In one of more alternative embodiments of the present disclosure, other position detection devices may be used in place of, or in addition to an accelerometer, and the analysis provided as part of those embodiments of the disclosure could be adjusted, if necessary to accommodate any differences needed to use the alternative position detection devices. A gyroscope is another example of a device which can determine a change in a position of a person. While an accelerometer may give greater sensitivity to linear changes in position, a gyroscope may have greater sensitivity for angular motion, and may be considered an appropriate component for use with specific types of seizures or for specific patients who may experience seizures in which angular motion is an important component. Other position detection devices could also be used as part of the present disclosure.
The first predetermined threshold may be determined empirically. The predetermined threshold may be set in a factory to a specific value or may be set (or adjusted) by a physician supervising the condition of a patient. The predetermined threshold might vary for different patients, who might experience widely varying degrees of movement during seizure, or for different types of seizure conditions. One or more embodiments of the present disclosure may include a learning function for determining the first predetermined threshold. For example, a patient who is very athletic or who is engaged in certain vigorous activities, such as dance, gymnastics or martial arts, may make abrupt movements during ordinary activity. If the device renders false positives because the predetermined threshold is set too low, a feedback mechanism may be used to help the device “learn” to screen out false positives. This learning process may be provided acutely in a real-time fashion, chronically over a long period using neural networks and pattern recognition based approaches, or a combination thereof.
If the dynamic activity is not greater than the predetermined first threshold, an advisory that there has been a “Non-Seizure” event may be sent 225 to the display, while accelerometer data continues to be received at the processor. If the accelerometer dynamic activity is greater than the predetermined first threshold, a seizure event is detected 228 and a “Seizure Event” advisory may be sent 230 to the display and the warning device may be activated 235. When activated 235, the warning device could, for example, activate an alarm with a sound or a vibration. The warning device could also place a call with a recorded message, or send a message, such as an e-mail or a text message, to one or more designated persons.
In some patients, a seizure may manifest as a cessation of movement; that is, the patient may be motionless and/or appear to be in a coma. In such a case or for such conditions, in accordance with one of more embodiments of the present disclosure, if the accelerometer dynamic activity is less than a predetermined first threshold having a low value, a “Seizure Event” advisory may be sent 230 to the display and the warning device may be activated 235. In one or more embodiments of the present disclosure, there could be a first high pre-determined threshold and a first low predetermined threshold, with a “Seizure Event” advisory being sent 230 to the display and the warning device being activated 235 both if the accelerometer dynamic activity is less than the first low predetermined threshold or if the accelerometer dynamic activity is more than the first high predetermined threshold.
Continuing to refer to
Like the first predetermined threshold, the second predetermined threshold may be determined empirically or based on adaptive learning over time. The second predetermined threshold may be set at a factory or may be set (or adjusted) by a treating physician to reflect the situation of a particular patient or condition being treated. As with the first pre-determined threshold, the value of the second predetermined threshold may be set low for a seizure manifesting as a cessation of movement, so that if the maximum frequency is less than the predetermined first threshold, a “Seizure Event” advisory is sent 330 to the display and the warning device is activated 335. And in one or more embodiments of the present disclosure, there could be a second high predetermined threshold and a second low predetermined threshold used, with a “Seizure Event” advisory being sent 330 to the display and the warning device being activated 335 both if the maximum frequency is less than the second low predetermined threshold or if the maximum frequency is more than the second high predetermined threshold.
Continuing to refer to
Referring again to
The processor 420 may be configured to determine, at 416, whether the acceleration data 406 indicates an event is a seizure event or a non-seizure event by applying a non-linear operator to the acceleration data 406. Application of the non-linear operator to the acceleration data 406 by the processor 420 may include a calculation, at 418, of the non-linear energy of the acceleration data and performance, at 422, of at least one secondary analysis to determine whether the event is a seizure.
The processor 420 may be further configured to use physiological monitoring systems other than, or in addition to, the accelerometer 405, indicate an event. The physiological monitoring systems may include the EKG monitoring system 410, the respiration monitoring system 450, the skin resistivity monitoring system 480. For example, the processor 420 may be configured to determine, at 424, whether the EKG data 412 or (EKG measurements) indicates an event and/or whether the event is a seizure event. The processor 420 may be configured to use a relative heart rate detection algorithm 426 to support the determination of whether the event was a seizure. The processor 420 may be further configured to use a noise analysis 428 and/or noise filtering of the EKG data 412 (or EKG measurements) to determine whether to disregard the EKG data 412 in determining whether an event is a seizure when the level of noise in the EKG data 412 is too high. The processor 420 may be further configured to determine, at 432, whether the respiration data 455 indicates an event and/or whether the event is a seizure event. The processor 420 may be further configured to determine, at 490, whether the skin resistivity data 485 indicates an event and/or whether the event is a seizure event. A seizure event could be determined if only one of the accelerator data 406, the EKG data 412, and the respiration data 455 supports a seizure event, but in most cases, it is preferable that a seizure event is determined if the accelerator data 406, the EKG data 412, the respiration data 455, and skin resistivity data 485 all support a finding of a seizure event. (This would reduce false positive findings of a seizure.)
If there is an event, a determination is made as to whether it is a seizure event or a non-seizure event and an appropriate advisory 425 may be sent to the display 430. If the event is a seizure event, the processor 420 may be configured to send an activation signal 435 to the warning device 440. The activated warning device 440 could, for example, activate an alarm 465, such as with a sound or a vibration. The warning device 440 could also provide a message 470 to one or more designated persons. For example, the warning device could place a call with a recorded message, or send a message such as an e-mail or a text message.
Continuing to refer to
Referring again to
Continuing to refer to
In one or more embodiments of the present disclosure, when the seizure detection device detects a probable seizure, the seizure detection device could alert a SUDEP risk detection device, such as described in co-pending and commonly assigned application entitled “Methods, Systems and Apparatuses for Detecting Increased Risk of Sudden Death,” U.S. application Ser. No. 13/453,746, filed May 10, 2012 concurrently herewith, to activate the SUDEP device to a greater sensitivity. If the SUDEP device is programmed appropriately, the SUDEP detection device could respond to the alert by sending an acknowledgement to the seizure detection device of the instant disclosure. If the seizure device does not receive an acknowledgement, the processor could activate the warning device to issue an additional warning that the SUDEP detection device might not be functioning properly.
In one or more embodiments of the present disclosure, the accelerometer could include a setting to indicate when the patient will be engaged in different levels of activity, such as strenuous activity, normal activity, sedentary activity or sleeping. The activity levels could be linked to different predetermined thresholds, so that the thresholds are higher for more strenuous activity.
Continuing to refer to
Referring again to
In some embodiments of the present disclosure, the processor may determine that the EKG measurements contain too much noise and thus determine that the EKG measurements should be ignored. For example, if the application of the non-linear operator indicates substantial movement, it may indicate that there may be noise on the EKG from muscle movement. The processor may ignore the EKG measurements and instead assess whether other measurements, such as accelerometer data, are indicative of a seizure.
In one or more embodiments of the present disclosure, the combination of accelerometer data and EKG data collected may be used to classify the seizure types experienced by a patient. Thus, the patient's condition may be better diagnosed, classified and treated. Table 1 and Table 2 below depict how the collected accelerometer data and EKG data may be used for classification of seizure types:
Continuing to refer to
Referring again to
In alternate embodiments of the present disclosure, a seizure is determined to have occurred when two of three indicators (accelerometer data, physiological data or secondary analysis) are indicative of a seizure. Less commonly, but for use with certain patients, the present disclosure could be set so that a seizure is determined to have occurred when one of the three indicators is indicative of a seizure. As mentioned above, in alternative embodiments of the present disclosure, if the EKG measurements contain too much noise, the processor could ignore the EKG measurements and focus only on one or more other measurements, such as accelerometer data or physiological data, for detection of seizures.
The accelerometer of the present disclosure will preferably record the patient's proper acceleration “tri-axially.” This means that the accelerometer will preferably record the proper acceleration in each of the three directions X, Y and Z, as the patient stands up, sits down, walks, jumps, runs, lies still, etc. Plotted as a function of time, the proper acceleration data is sent to the processor from the accelerometer as three curves or functions, one for acceleration in each direction, with each as a function of time.
As previously described herein with respect to
The equation for a Lie Bracket in continuous time is:
L[y,x]≡x′y−xy′ EQ. 1
where L is the Lie Bracket of two functions y and x. The prime mark after the x and y indicates taking the derivative of the x and y with respect to time. (Two prime marks after an x, y, or z would indicate taking the second derivative.) Thus, to determine the Lie Bracket, L[y,x], one takes the derivative of x with respect to time, multiplied by y and subtracts from that the product of taking the derivative of y with respect to time multiplied by x.
The non-linear energy of the accelerometer data in the x direction, that is, of function x, such as acceleration in the x-direction, is denoted as Ψ(x):
Ψ(x)≡(x′)2−xx″=L[x′, x] EQ. 2
where Ψ(x) is defined as the derivative of x with respect to time, squared, minus the product of x multiplied by the second derivative of x with respect to time.
Different orders of Lie Bracket equations, where k represents the order and k=0, 1, 2, etc., may be:
Γk(x)≡L[x(k−1), x]=x′x(k−1)−xx(k) EQ. 3
As one looks at higher order Lie Brackets—that is as “k” increases—more weight is given to changes in amplitude of the signal and less weight is given to changes in frequency of the signal. In some patients, the seizure may cause more frequent changes in position (and thus more frequent changes in the acceleration), while others may have seizures with higher amplitude changes of position. Thus, one might adjust the sensitivity of the Lie Bracket, by selecting a different order equation, to better fit with the type of seizures that a particular patient is experiencing.
A second order Lie Bracket equation (k=2) might be selected and used in some preferred embodiments of the present disclosure for typical patient cases. The second order Lie Bracket equation for energy of the accelerometer data in the x direction, in discrete time intervals “n”, is Ψ(x[n]):
Ψ(x[n])≡x2[n]−x[n−1]*x[n+1] EQ. 4
As the data is coming from the accelerometer in three channels, one for acceleration in each direction x, y, and z, the processor of the present disclosure would apply Equation 4 (or another equation for a different order Lie Bracket equation) to the accelerometer data in each of three directions:
Ψ(x[n])≡x2[n]−x[n−1]*x[n+1] EQ. 4, for x direction
Ψ(y[n])≡y2[n]−y[n−1]*y[n+1] EQ. 4 for y direction
Ψ(z[n])≡z2[n]−z[n−1]*z[n+1] EQ. 4 for z direction
After calculating the energy Ψ for proper acceleration in each direction, the processor may average the three values of Ψ (one for each direction) to obtain an average Ψ. The average Ψ could be used to determine whether an event has occurred, as in, for example, at 210 of
But in some embodiments of the present disclosure, the processor may perform comparisons between the values of Ψ obtained for the different directions or focus on values of Ψ obtained for specific directions. For example, the processor could be set to a special mode when the patient is asleep.
In some embodiments, multiple thresholds may also be used to detect spikes within predefined energy ranges. Larger spikes, or spikes in higher energy ranges, may be more indicative of a seizure event; however, it may still be beneficial to detect smaller spikes, or spikes in lower energy ranges, as these may be indicative of seizure events, or particular phases of a seizure event. Using multiple thresholds may increase the granularity of the spike and seizure detection. The multiple thresholds may be used to train a spike and/or seizure detection algorithm to a particular patient's seizure signature to improve detection accuracy.
In light of the principles and example embodiments described and illustrated herein, it will be recognized that the example embodiments can be modified in arrangement and detail without departing from such principles. Also, the foregoing discussion has focused on particular embodiments, but other configurations are contemplated. In particular, even though expressions such as “in one embodiment,” “in another embodiment,” or the like are used herein, these phrases are meant to generally reference embodiment possibilities, and are not intended to limit the disclosure to particular embodiment configurations. As used herein, these terms may reference the same or different embodiments that are combinable into other embodiments.
Similarly, although example processes have been described with regard to particular operations performed in a particular sequence, numerous modifications could be applied to those processes to derive numerous alternative embodiments of the present disclosure. For example, alternative embodiments may include processes that use fewer than all of the disclosed operations, processes that use additional operations, and processes in which the individual operations disclosed herein are combined, subdivided, rearranged, or otherwise altered.
This disclosure also described various benefits and advantages that may be provided by various embodiments. One, some, all, or different benefits or advantages may be provided by different embodiments.
In view of the wide variety of useful permutations that may be readily derived from the example embodiments described herein, this detailed description is intended to be illustrative only, and should not be taken as limiting the scope of the invention. What is claimed as the invention, therefore, are all implementations that come within the scope of the following claims, and all equivalents to such implementations.
Number | Name | Date | Kind |
---|---|---|---|
4197856 | Northrop | Apr 1980 | A |
RE30530 | Hopwood | Feb 1981 | E |
4320766 | Alihanka et al. | Mar 1982 | A |
5062169 | Kennedy et al. | Nov 1991 | A |
5090410 | Saper et al. | Feb 1992 | A |
5168874 | Segalowitz | Dec 1992 | A |
5194847 | Taylor et al. | Mar 1993 | A |
5213568 | Lattin et al. | May 1993 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5349962 | Lockard et al. | Sep 1994 | A |
5423325 | Burton | Jun 1995 | A |
5503159 | Burton | Apr 1996 | A |
5511553 | Segalowitz | Apr 1996 | A |
5513649 | Gevins et al. | May 1996 | A |
5523742 | Simkins et al. | Jun 1996 | A |
5549650 | Bornzin et al. | Aug 1996 | A |
5610590 | Johnson et al. | Mar 1997 | A |
5645077 | Foxlin | Jul 1997 | A |
5702323 | Poulton | Dec 1997 | A |
5748113 | Torch | May 1998 | A |
5807284 | Foxlin | Sep 1998 | A |
5808552 | Wiley et al. | Sep 1998 | A |
5810722 | Heikkila | Sep 1998 | A |
5853005 | Scanlon | Dec 1998 | A |
5876350 | Lo et al. | Mar 1999 | A |
5879309 | Johnson et al. | Mar 1999 | A |
5905436 | Dwight et al. | May 1999 | A |
5916181 | Socci et al. | Jun 1999 | A |
5978972 | Stewart et al. | Nov 1999 | A |
6009349 | Mouchawar et al. | Dec 1999 | A |
6048324 | Socci et al. | Apr 2000 | A |
6052619 | John | Apr 2000 | A |
6058328 | Levine et al. | May 2000 | A |
6066075 | Poulton | May 2000 | A |
6095991 | Krausman et al. | Aug 2000 | A |
6104947 | Heikkila et al. | Aug 2000 | A |
6134474 | Fischell et al. | Oct 2000 | A |
6162191 | Foxlin | Dec 2000 | A |
6163281 | Torch | Dec 2000 | A |
6216537 | Henschel et al. | Apr 2001 | B1 |
6246344 | Torch | Jun 2001 | B1 |
6277080 | Nissilä et al. | Aug 2001 | B1 |
6315719 | Rode et al. | Nov 2001 | B1 |
6315740 | Singh | Nov 2001 | B1 |
6356784 | Lozano et al. | Mar 2002 | B1 |
6361507 | Foxlin | Mar 2002 | B1 |
6361508 | Johnson et al. | Mar 2002 | B1 |
6377845 | Kinast | Apr 2002 | B1 |
6385486 | John et al. | May 2002 | B1 |
6405077 | Birnbaum et al. | Jun 2002 | B1 |
6411841 | Heikkilä | Jun 2002 | B2 |
6416471 | Kumar et al. | Jul 2002 | B1 |
6428476 | Heikkilä et al. | Aug 2002 | B1 |
6441731 | Hess | Aug 2002 | B1 |
6454708 | Ferguson et al. | Sep 2002 | B1 |
6463328 | John | Oct 2002 | B1 |
6466820 | Juran et al. | Oct 2002 | B1 |
6495601 | Hochman | Dec 2002 | B1 |
6496705 | Ng et al. | Dec 2002 | B1 |
6537227 | Kinnunen et al. | Mar 2003 | B2 |
6539263 | Schiff et al. | Mar 2003 | B1 |
6540686 | Heikkilä et al. | Apr 2003 | B2 |
6542081 | Torch | Apr 2003 | B2 |
6605044 | Bimbaum | Aug 2003 | B2 |
6611783 | Kelly, Jr. et al. | Aug 2003 | B2 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6629990 | Putz et al. | Oct 2003 | B2 |
6644321 | Behm | Nov 2003 | B1 |
6652478 | Gartstein et al. | Nov 2003 | B1 |
6687535 | Hautala et al. | Feb 2004 | B2 |
6730047 | Socci et al. | May 2004 | B2 |
6763256 | Kimball et al. | Jul 2004 | B2 |
6786877 | Foxlin | Sep 2004 | B2 |
6793670 | Osorio et al. | Sep 2004 | B2 |
6804558 | Haller et al. | Oct 2004 | B2 |
6808473 | Hisano et al. | Oct 2004 | B2 |
6819956 | DiLorenzo | Nov 2004 | B2 |
6847892 | Zhou et al. | Jan 2005 | B2 |
6850601 | Jones, III et al. | Feb 2005 | B2 |
6879850 | Kimball | Apr 2005 | B2 |
6923784 | Stein | Aug 2005 | B2 |
6931274 | Williams | Aug 2005 | B2 |
6931277 | Yuzhakov et al. | Aug 2005 | B1 |
6980852 | Jersey-Willuhn et al. | Dec 2005 | B2 |
6984993 | Ariav | Jan 2006 | B2 |
7024247 | Gliner et al. | Apr 2006 | B2 |
7034008 | Donahue et al. | Apr 2006 | B2 |
7035684 | Lee | Apr 2006 | B2 |
7057053 | Beatch et al. | Jun 2006 | B2 |
7062313 | Nissilä | Jun 2006 | B2 |
7068842 | Liang et al. | Jun 2006 | B2 |
7077810 | Lange et al. | Jul 2006 | B2 |
7101877 | Bain et al. | Sep 2006 | B2 |
7104947 | Riehl | Sep 2006 | B2 |
7110820 | Tcheng et al. | Sep 2006 | B2 |
7112319 | Broderick et al. | Sep 2006 | B2 |
7127370 | Kelly, Jr. et al. | Oct 2006 | B2 |
7146211 | Frei et al. | Dec 2006 | B2 |
7146218 | Esteller et al. | Dec 2006 | B2 |
7149773 | Haller et al. | Dec 2006 | B2 |
7167743 | Heruth et al. | Jan 2007 | B2 |
7169107 | Jersey-Willuhn et al. | Jan 2007 | B2 |
7177678 | Osorio et al. | Feb 2007 | B1 |
7181505 | Haller et al. | Feb 2007 | B2 |
7184820 | Jersey-Willuhn et al. | Feb 2007 | B2 |
7200439 | Zdeblick et al. | Apr 2007 | B2 |
7203548 | Whitehurst et al. | Apr 2007 | B2 |
7206630 | Tarler | Apr 2007 | B1 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7244769 | Epstein et al. | Jul 2007 | B2 |
7257438 | Kinast | Aug 2007 | B2 |
7259184 | Beatch et al. | Aug 2007 | B2 |
7274298 | Frank | Sep 2007 | B2 |
7285090 | Stivoric et al. | Oct 2007 | B2 |
7289850 | Burnes et al. | Oct 2007 | B2 |
7292890 | Whitehurst et al. | Nov 2007 | B2 |
7304580 | Sullivan et al. | Dec 2007 | B2 |
7313440 | Miesel | Dec 2007 | B2 |
7314451 | Halperin et al. | Jan 2008 | B2 |
7330760 | Heruth et al. | Feb 2008 | B2 |
7361141 | Nissila et al. | Apr 2008 | B2 |
7376463 | Salo et al. | May 2008 | B2 |
7385443 | Denison | Jun 2008 | B1 |
7387607 | Holt et al. | Jun 2008 | B2 |
7389147 | Wahlstrand et al. | Jun 2008 | B2 |
7395113 | Heruth et al. | Jul 2008 | B2 |
7396330 | Banet et al. | Jul 2008 | B2 |
7416541 | Yuzhakov et al. | Aug 2008 | B2 |
7418292 | Shafer | Aug 2008 | B2 |
7420472 | Tran | Sep 2008 | B2 |
7447545 | Heruth et al. | Nov 2008 | B2 |
7454245 | Armstrong et al. | Nov 2008 | B2 |
7477934 | Nissilä et al. | Jan 2009 | B2 |
7488293 | Marcovecchio et al. | Feb 2009 | B2 |
7488294 | Torch | Feb 2009 | B2 |
7491181 | Heruth et al. | Feb 2009 | B2 |
7494464 | Rzesnitzek et al. | Feb 2009 | B2 |
7499742 | Bolea et al. | Mar 2009 | B2 |
7502643 | Farringdon et al. | Mar 2009 | B2 |
7515054 | Torch | Apr 2009 | B2 |
7517328 | Hoffmann | Apr 2009 | B2 |
7524879 | Beatch et al. | Apr 2009 | B2 |
7534790 | Bain et al. | May 2009 | B2 |
7539532 | Tran | May 2009 | B2 |
7539533 | Tran | May 2009 | B2 |
7539543 | Schiff et al. | May 2009 | B2 |
7542807 | Bertolero et al. | Jun 2009 | B2 |
7542878 | Nanikashvili | Jun 2009 | B2 |
7558622 | Tran | Jul 2009 | B2 |
7565132 | Ben Ayed | Jul 2009 | B2 |
7585839 | Larsen et al. | Sep 2009 | B2 |
7590453 | Heruth et al. | Sep 2009 | B2 |
7619005 | Epstein et al. | Nov 2009 | B2 |
7620456 | Gliner et al. | Nov 2009 | B2 |
7629890 | Sullivan et al. | Dec 2009 | B2 |
7643655 | Liang et al. | Jan 2010 | B2 |
7647121 | Wahlstrand et al. | Jan 2010 | B2 |
7654957 | Abreu | Feb 2010 | B2 |
7658112 | Nakamura | Feb 2010 | B2 |
7662105 | Hatlestad | Feb 2010 | B2 |
7666121 | Zhou | Feb 2010 | B2 |
7668588 | Kovacs | Feb 2010 | B2 |
7676269 | Yun et al. | Mar 2010 | B2 |
7684854 | Park et al. | Mar 2010 | B2 |
7714757 | Denison et al. | May 2010 | B2 |
7717848 | Heruth et al. | May 2010 | B2 |
7720547 | Denker et al. | May 2010 | B2 |
RE41376 | Torch | Jun 2010 | E |
7733224 | Tran | Jun 2010 | B2 |
7738952 | Yun et al. | Jun 2010 | B2 |
7738958 | Zdeblick et al. | Jun 2010 | B2 |
7747301 | Cheng et al. | Jun 2010 | B2 |
7747318 | John et al. | Jun 2010 | B2 |
7769442 | Shafer | Aug 2010 | B2 |
7769464 | Gerber et al. | Aug 2010 | B2 |
7775993 | Heruth et al. | Aug 2010 | B2 |
7783362 | Whitehurst et al. | Aug 2010 | B2 |
7787946 | Stahmann et al. | Aug 2010 | B2 |
7790945 | Watson, Jr. | Sep 2010 | B1 |
7792583 | Miesel et al. | Sep 2010 | B2 |
7801603 | Westlund et al. | Sep 2010 | B2 |
7801618 | Pless | Sep 2010 | B2 |
7801743 | Graves et al. | Sep 2010 | B2 |
7809442 | Bolea et al. | Oct 2010 | B2 |
7813802 | Tcheng et al. | Oct 2010 | B2 |
7813812 | Kieval et al. | Oct 2010 | B2 |
7822481 | Gerber et al. | Oct 2010 | B2 |
7827011 | DeVaul et al. | Nov 2010 | B2 |
7831305 | Gliner | Nov 2010 | B2 |
7847628 | Denison | Dec 2010 | B2 |
7848817 | Janzig et al. | Dec 2010 | B2 |
7860570 | Whitehurst et al. | Dec 2010 | B2 |
7862826 | Murphy et al. | Jan 2011 | B2 |
7863188 | Tsurume et al. | Jan 2011 | B2 |
7865244 | Giftakis et al. | Jan 2011 | B2 |
7866212 | Ariav et al. | Jan 2011 | B2 |
7875611 | Bain et al. | Jan 2011 | B2 |
7881780 | Flaherty | Feb 2011 | B2 |
7884727 | Tran | Feb 2011 | B2 |
7899527 | Yun et al. | Mar 2011 | B2 |
7899539 | Whitehurst et al. | Mar 2011 | B2 |
7899545 | John | Mar 2011 | B2 |
7904158 | Stegemann et al. | Mar 2011 | B2 |
7925348 | Bornzin et al. | Apr 2011 | B1 |
7931592 | Currie et al. | Apr 2011 | B2 |
7935076 | Estes et al. | May 2011 | B2 |
7945316 | Giftakis et al. | May 2011 | B2 |
7953485 | Salo et al. | May 2011 | B2 |
RE42471 | Torch | Jun 2011 | E |
7957809 | Bourget et al. | Jun 2011 | B2 |
7957820 | Bertolero et al. | Jun 2011 | B2 |
7959567 | Stivoric et al. | Jun 2011 | B2 |
7965833 | Meir et al. | Jun 2011 | B2 |
7974671 | Fujiwara et al. | Jul 2011 | B2 |
7985185 | De Voir et al. | Jul 2011 | B2 |
7991460 | Fischell et al. | Aug 2011 | B2 |
7991461 | Flaherty et al. | Aug 2011 | B2 |
7996076 | Burns et al. | Aug 2011 | B2 |
7999857 | Bunn et al. | Aug 2011 | B2 |
8000789 | Denison | Aug 2011 | B2 |
8000794 | Lozano | Aug 2011 | B2 |
8002701 | John et al. | Aug 2011 | B2 |
8008283 | Hochman et al. | Aug 2011 | B2 |
8010194 | Muller | Aug 2011 | B2 |
8021299 | Miesel et al. | Sep 2011 | B2 |
8027730 | John | Sep 2011 | B2 |
8027737 | Kokones et al. | Sep 2011 | B2 |
8032213 | Qu et al. | Oct 2011 | B1 |
8041418 | Giftakis et al. | Oct 2011 | B2 |
8041419 | Giftakis et al. | Oct 2011 | B2 |
8060194 | Flaherty | Nov 2011 | B2 |
8060206 | Kieval et al. | Nov 2011 | B2 |
8060219 | Ross et al. | Nov 2011 | B2 |
8066650 | Lee et al. | Nov 2011 | B2 |
8068911 | Giftakis et al. | Nov 2011 | B2 |
8070695 | Gupta et al. | Dec 2011 | B2 |
8075499 | Nathan et al. | Dec 2011 | B2 |
8079968 | Hoffmann | Dec 2011 | B2 |
8084663 | Watson, Jr. | Dec 2011 | B2 |
8103333 | Tran | Jan 2012 | B2 |
8103351 | Gerber et al. | Jan 2012 | B2 |
8108036 | Tran | Jan 2012 | B2 |
8108038 | Giftakis et al. | Jan 2012 | B2 |
8108046 | Giftakis et al. | Jan 2012 | B2 |
8109891 | Kramer et al. | Feb 2012 | B2 |
8112148 | Giftakis et al. | Feb 2012 | B2 |
8112153 | Giftakis et al. | Feb 2012 | B2 |
8114021 | Robertson et al. | Feb 2012 | B2 |
8121673 | Tran | Feb 2012 | B2 |
8121690 | Yun et al. | Feb 2012 | B2 |
8121694 | Molnar et al. | Feb 2012 | B2 |
8140143 | Picard et al. | Mar 2012 | B2 |
8157731 | Teller et al. | Apr 2012 | B2 |
8172459 | Abreu | May 2012 | B2 |
8172777 | Goto | May 2012 | B2 |
8180440 | McCombie et al. | May 2012 | B2 |
8200320 | Kovacs | Jun 2012 | B2 |
8200321 | McCombie et al. | Jun 2012 | B2 |
8209009 | Giftakis et al. | Jun 2012 | B2 |
8209019 | Giftakis et al. | Jun 2012 | B2 |
8214007 | Baker et al. | Jul 2012 | B2 |
8214035 | Giftakis et al. | Jul 2012 | B2 |
8229535 | Mensinger et al. | Jul 2012 | B2 |
8239010 | Banet et al. | Aug 2012 | B2 |
8249731 | Tran et al. | Aug 2012 | B2 |
8265907 | Nanikashvili et al. | Sep 2012 | B2 |
8290574 | Feild et al. | Oct 2012 | B2 |
8290577 | Brooks et al. | Oct 2012 | B2 |
8290596 | Wei et al. | Oct 2012 | B2 |
8301575 | Bonnet et al. | Oct 2012 | B2 |
8311620 | Qu et al. | Nov 2012 | B2 |
8311645 | Bolea et al. | Nov 2012 | B2 |
8317776 | Ferren et al. | Nov 2012 | B2 |
8321004 | Moon et al. | Nov 2012 | B2 |
8323188 | Tran | Dec 2012 | B2 |
8323189 | Tran et al. | Dec 2012 | B2 |
8326419 | Rosenberg et al. | Dec 2012 | B2 |
8328420 | Abreu | Dec 2012 | B2 |
8328718 | Tran | Dec 2012 | B2 |
8333874 | Currie | Dec 2012 | B2 |
8352034 | Berg et al. | Jan 2013 | B2 |
8364250 | Moon et al. | Jan 2013 | B2 |
8369936 | Farringdon et al. | Feb 2013 | B2 |
8386032 | Bachinski et al. | Feb 2013 | B2 |
8396537 | Balji et al. | Mar 2013 | B2 |
8398546 | Pacione et al. | Mar 2013 | B2 |
8398560 | Elser | Mar 2013 | B2 |
8401646 | Stadler et al. | Mar 2013 | B2 |
8403881 | Ferren et al. | Mar 2013 | B2 |
8406868 | Buschman et al. | Mar 2013 | B2 |
8410078 | Liang et al. | Apr 2013 | B2 |
8417343 | Bolea et al. | Apr 2013 | B2 |
8419649 | Banet et al. | Apr 2013 | B2 |
8423134 | Buschman et al. | Apr 2013 | B2 |
8425415 | Tran | Apr 2013 | B2 |
8428720 | Corbucci et al. | Apr 2013 | B2 |
8428727 | Bolea et al. | Apr 2013 | B2 |
8435738 | Holmes | May 2013 | B2 |
8437824 | Moon et al. | May 2013 | B2 |
8443634 | Scheffler et al. | May 2013 | B2 |
8447401 | Miesel et al. | May 2013 | B2 |
8449471 | Tran | May 2013 | B2 |
8452409 | Bachinski et al. | May 2013 | B2 |
20010032059 | Kelly, Jr. et al. | Oct 2001 | A1 |
20020177882 | DiLorenzo | Nov 2002 | A1 |
20030236474 | Singh | Dec 2003 | A1 |
20040111045 | Sullivan et al. | Jun 2004 | A1 |
20060212097 | Varadan et al. | Sep 2006 | A1 |
20060290516 | Muehlsteff et al. | Dec 2006 | A1 |
20070249470 | Niva et al. | Oct 2007 | A1 |
20070276200 | Ahola et al. | Nov 2007 | A1 |
20070287928 | Kiviniemi et al. | Dec 2007 | A1 |
20080081958 | Denison et al. | Apr 2008 | A1 |
20080134862 | Lumme et al. | Jun 2008 | A1 |
20080150731 | Laukkanen et al. | Jun 2008 | A1 |
20080214359 | Niva et al. | Sep 2008 | A1 |
20080281376 | Gerber et al. | Nov 2008 | A1 |
20080319281 | Aarts | Dec 2008 | A1 |
20090030345 | Bonnet et al. | Jan 2009 | A1 |
20090060287 | Hyde et al. | Mar 2009 | A1 |
20090099627 | Molnar et al. | Apr 2009 | A1 |
20090105785 | Wei et al. | Apr 2009 | A1 |
20090115618 | Tuulari | May 2009 | A1 |
20090137921 | Kramer et al. | May 2009 | A1 |
20090156944 | Kinnunen et al. | Jun 2009 | A1 |
20090216143 | Tulppo et al. | Aug 2009 | A1 |
20100049006 | Magar et al. | Feb 2010 | A1 |
20100121214 | Giftakis et al. | May 2010 | A1 |
20100137735 | Hoppe | Jun 2010 | A1 |
20100228103 | Schecter | Sep 2010 | A1 |
20100268056 | Picard et al. | Oct 2010 | A1 |
20100280574 | Carlson et al. | Nov 2010 | A1 |
20100298661 | McCombie et al. | Nov 2010 | A1 |
20100305665 | Miesel et al. | Dec 2010 | A1 |
20100312188 | Robertson et al. | Dec 2010 | A1 |
20110060252 | Simonsen et al. | Mar 2011 | A1 |
20110066081 | Goto | Mar 2011 | A1 |
20110230730 | Quigg et al. | Sep 2011 | A1 |
Entry |
---|
Pardalos, Nonlinear Dynamical Systems and Adaptive Filters in Biomedicine, 2003, Annals of Operations Research, No. 119, pp. 119-142. |
Zio Card, “Event cardiac activity recording device”, iRhythm, San Francisco, CA, Mar. 2009, 2 pages. |
Number | Date | Country | |
---|---|---|---|
20140031635 A1 | Jan 2014 | US |